This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Vera Therapeutics (VERA)

Tipranks - Tipranks - Wed Jun 3, 12:12PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Disc Medicine (IRON) and Vera Therapeutics (VERA) with bullish sentiments.

Claim 55% Off TipRanks

Disc Medicine (IRON)

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Disc Medicine, with a price target of $100.00. The company’s shares closed last Tuesday at $68.54, close to its 52-week high of $68.73.

According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 31.7% and a 55.4% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., MoonLake Immunotherapeutics, and Amylyx Pharmaceuticals Inc. ;'>

Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $100.63, implying a 41.5% upside from current levels. In a report issued on May 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $118.00 price target.

See the top stocks recommended by analysts >>

Vera Therapeutics (VERA)

In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on Vera Therapeutics. The company’s shares closed last Tuesday at $32.09.

According to TipRanks.com, Deschner is a 5-star analyst with an average return of 44.3% and a 69.4% success rate. Deschner covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Mirum Pharmaceuticals, and Korro Bio. ;'>

Currently, the analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $77.63, which is a 125.4% upside from current levels. In a report issued on May 22, J.P. Morgan also maintained a Buy rating on the stock with a $86.00 price target.

Read More on IRON:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).